Open AccessPharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors
Author(s) -
Samuel J. Reddick,
Olivia Campagne,
Jie Huang,
Arzu OnarThomas,
Alberto Broniscer,
Amar Gajjar,
Clinton F. Stewart
Publication year - 2019
Publication title -
cancer chemotherapy and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.112
H-Index - 111
eISSN - 1432-0843
pISSN - 0344-5704
DOI - 10.1007/s00280-019-03921-3
Subject(s) - erlotinib , pharmacokinetics , medicine , rash , pharmacology , tyrosine kinase inhibitor , population , gastroenterology , oncology , epidermal growth factor receptor , cancer , environmental health
Erlotinib (Tarceva ® ), a potent small molecule inhibitor of the epidermal growth factor receptor tyrosine kinase, has been evaluated to treat infants and children with primary brain tumors. The pharmacokinetics of erlotinib and its primary metabolite OSI-420 were characterized and exposure-safety associations were investigated.